Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma

Urothelial carcinoma (UC) occupies a high incidence among all the genitourinary malignancies. Immune checkpoint inhibitors (ICIs), as alternative treatments of metastatic urothelial carcinoma (mUC), have been applied in the treatment of mUC after chemotherapy failure, with comparable efficacy and sa...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Di Wang, Kai Sun, Tianqi Wang, Dongxu Zhang, Fengze Sun, Yuanshan Cui, Hongwei Zhao, Jitao Wu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2021-11-01
Edice:	Frontiers in Pharmacology
Témata:	urothelial carcinoma (UC) immune checkpoint inhibitor (ICI) immune-related adverse events (irAEs) programmed cell death protein 1 (PD1) programmed cell death ligand protein 1 (PD-L1)
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fphar.2021.710943/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!